CLINICAL_TRIALS
trial_result
· 2024-09-26
Clinical Trial Update: Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma [Phase 1]
Summary
Amgen completed a Phase 1b study of OPomD for relapsed or refractory multiple myeloma, with results posted in 2024.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Amgen | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 1 | Status: COMPLETED | Results posted: 2024-09-26